ALK kinase is another druggable target in NSCLC patients who do not respond to EGFR inhibitors or have EGFR wild-type tumors; ALK activation may be associated with resistance to EGFR tyrosine kinase inhibitor27, 28. Here, ALK is linked to non-small cell lung carcinoma.